Neflamapimod Shows Promise in Dementia with Lewy Bodies Study
CervoMed announced positive 16-week results from the extension phase of its Phase 2b RewinD-LB study of neflamapimod for dementia...
ACTG Reveals Promising SLIM Liver Findings at CROI
The AIDS Clinical Trials Group (ACTG) presented findings from their SLIM LIVER study at the 2025 Conference on Retroviruses...
Eradivir’s EV25 Flu Challenge Study in Healthy Adults
Eradivir, a clinical-stage immunotherapy company, launched a Phase 2 challenge study for its antiviral therapeutic, EV25, to evaluate its...
4DMT Announces First Patients in Phase 3 Trial of 4D-150 for Wet AMD
4D Molecular Therapeutics (4DMT) has initiated its Phase 3 clinical trial, 4FRONT-1, for 4D-150, a potential treatment for wet...
Calidi Delivers Transient Gene Therapy to Tumors
Calidi Biotherapeutics announced preclinical success with its systemic RTNova platform, demonstrating effective delivery of gene therapy payloads to targeted...
Tonix Single-Dose Mpox & Smallpox Vaccine Candidate Awarded Grant
Tonix Pharmaceuticals has received a grant from the Medical CBRN Defense Consortium (MCDC) to further develop TNX-801, a single-dose...
Merck on Investigator-Initiated Studies and Budgeting Practices at 2025 SCOPE Summit
The 2025 SCOPE Summit’s panel discussion on investigator-initiated studies (IIS) delved into the complexities of budgeting practices, highlighting the...
Blueberries Medical Announces C$1 Million Private Placement
Blueberries Medical Corp. is raising approximately C$1.05 million (US$740,000) through a non-brokered private placement of 96,064,935 common shares at...
Artax Biopharma Unveils Promising Preclinical Data on NCK Modulators at 2025 AAD Annual Meeting
Artax Biopharma presented preclinical data on Nck modulators for atopic dermatitis at the 2025 American Academy of Dermatology Annual...
PDS Biotech Launches Phase 3 Trial of Versamune® in HPV16+ Head and Neck Cancer
PDS Biotechnology Corporation has launched VERSATILE-003, a Phase 3 clinical trial for its immunotherapy drug, Versamune® HPV. The trial...